Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02356302 · ClinicalTrials.gov registry record · Phase 1

Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
2
Study locations

NCT02356302 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02356302, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

Research is currently underway to develop new HIV prevention strategies. Intravaginal rings (IVRs) are one drug delivery method that is currently being studied. This study will evaluate the safety and pharmacokinetics of IVRs containing vicriviroc, MK-2048, and a combination of vicriviroc/MK-2048, in healthy, HIV-uninfected women.

Conditions Studied

HIV Infections

Interventions

  • DEVICE Vicriviroc (MK-4176) Intravaginal Ring (IVR)
  • DEVICE MK-2048 IVR
  • DEVICE MK-2048A IVR
  • DEVICE Placebo IVR

Study Locations (2)

Alabama

  • Alabama CRS - Birmingham

Pennsylvania

  • University of Pittsburgh CRS - Pittsburgh

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2015-05
Est. Completion 2016-03
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02356302

The ClinicalTrials.gov registry entry for NCT02356302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Vicriviroc (MK-4176) Intravaginal Ring (IVR) is the first listed.

NCT02356302 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02356302 about?

NCT02356302 is a clinical study titled "Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048". Research is currently underway to develop new HIV prevention strategies. Intravaginal rings (IVRs) are one drug delivery method that is currently being studied. This study will evaluate the safety and pharmacokinetics of IVRs containing vicriviroc, MK-2048, and a combination of vicriviroc/MK-2048, i...

What is the current status of trial NCT02356302?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-05. Estimated completion is 2016-03.

What conditions does trial NCT02356302 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT02356302?

The interventions under investigation include: Vicriviroc (MK-4176) Intravaginal Ring (IVR) (DEVICE), MK-2048 IVR (DEVICE), MK-2048A IVR (DEVICE), Placebo IVR (DEVICE).

Who is sponsoring clinical trial NCT02356302?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02356302 being conducted?

This trial has 2 study locations across Alabama, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.